63 related articles for article (PubMed ID: 21275180)
21. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
[No Abstract] [Full Text] [Related]
22. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study.
Louzã MR; Marques AP; Elkis H; Bassitt D; Diegoli M; Gattaz WF
Schizophr Res; 2004 Feb; 66(2-3):97-100. PubMed ID: 15061241
[TBL] [Abstract][Full Text] [Related]
23. An importance of dose in antipsychotic combination therapy for schizophrenia.
Suzuki T
J Clin Psychopharmacol; 2011 Jun; 31(3):399; author reply 399-400. PubMed ID: 21532376
[No Abstract] [Full Text] [Related]
24. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
25. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
26. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
27. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
[TBL] [Abstract][Full Text] [Related]
28. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Kane JM; Potkin SG; Daniel DG; Buckley PF
J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
[TBL] [Abstract][Full Text] [Related]
30. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
31. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
32. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Lee BJ; Lee JG; Kim YH
J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
[TBL] [Abstract][Full Text] [Related]
33. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
[TBL] [Abstract][Full Text] [Related]
34. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
Levinson I; Levine S
Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
[No Abstract] [Full Text] [Related]
35. Neuroleptic-potentiating effect of metyrosine.
Magelund G; Gerlach J; Casey DE
Am J Psychiatry; 1979 May; 136(5):732. PubMed ID: 35016
[No Abstract] [Full Text] [Related]
36. Haloperidol vs. Low-Potency Antipsychotic Drugs for Schizophrenia.
Bryan TL
Am J Nurs; 2015 Jul; 115(7):21. PubMed ID: 26110946
[No Abstract] [Full Text] [Related]
37. [Clinical study of shuizhi-dahuang mixture in treating schizophrenics with blood stasis syndrome].
Zhu YZ; Kang B; Zhu QQ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Nov; 16(11):646-8. PubMed ID: 9772611
[TBL] [Abstract][Full Text] [Related]
38. An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
McEvoy JP
CNS Spectr; 2006 Jul; 11(7 Suppl 7):4-8. PubMed ID: 16816794
[No Abstract] [Full Text] [Related]
39. [Neuroleptics in the treatment of schizophrenia spectrum disorders (a pharmacoepidemiological outpatient study)].
Kharaburova TL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(3 Pt 1):63-7. PubMed ID: 22677759
[No Abstract] [Full Text] [Related]
40. Lithium withdrawal trial in chronic schizophrenia.
Delva NJ; Letemendia FJ; Prowse AW
Br J Psychiatry; 1982 Oct; 141():401-6. PubMed ID: 6129017
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
